

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|--------------------------------------|-------------------|---|---------------------|
| Applicants: | Schwerts et al |) | |
| | |) | |
| Serial No.: | 10/525,278 |) | Examiner: S. Bausch |
| | |) | |
| Filed: | November 21, 2005 |) | Art Unit: 1634 |
| | |) | |
| For SINGLE NUCLEOTIDE POLYMORPHISMS) | |) | |
| SENSITIVELY PREDICTING ADVERSE) | |) | |
| DRUG REACTIONS (ADR) AND DRUG) | |) | |
| EFFICACY) | |) | |
| | |) | |

RESPONSE TO RESTRICTION REQUIRMENT**VIA EFS**

Commissioner for Patents
 PO BOX 1450
 Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement dated March 26, 2008, applicants hereby provisionally elect the invention of Group 1 with traverse. Applicants note that claims 17-18 are linking claims which link the inventions of Groups 1-6. Upon allowance of linking claims 17 or 18, the restriction requirement will be withdrawn.

Further, applicants elect SEQ ID NOs: 469-42(baySNP11594) with traverse. Applicants submit that they are entitled to a reasonable number of species and, further, that the restriction requirement on page 6 of the outstanding restriction requirement should be an election of species requirement.

Respectfully submitted,

April 28, 2008
 Date

/karla m weyand/
 Karla M. Weyand
 Registration No. 40,223

Siemens Healthcare Diagnostics Inc
 511 Benedict Ave
 Tarrytown, New York 15091
 Tel: 914-524-2741